warm auoimmune hemolytic anemia waiha epidemiology insights insight

DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia –Epidemiology Forecast—2034’ report delivers an in-depth understanding of Warm autoimmune hemolytic anemia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5
• Japan

Study Period: 2018-30

Warm Autoimmune Hemolytic Anemia Disease Understanding

Autoimmune Hemolytic Anemia (AIHA) is an acquired hemolytic disorder where antibodies directed against red blood cell (RBC) surface epitopes cause premature RBC destruction, which leads to anemia. Although rare, AIHA is one of the most common forms of acquired hemolytic disorders. AIHA can occur at any age but is most common among older adults, and the majority of AIHA individuals are above 40 years at diagnosis.

AIHAs may be primary (idiopathic) or secondary associated with several conditions (lymphoproliferative, autoimmune and infectious diseases, immunodeficiencies, solid tumors, transplants, and drugs) where the cited immunologic mechanisms are variably combined. Diagnosis may be easy, but some rare forms may be challenging, causing harmful delays in initiating appropriate therapy. Based on the isotype and thermal characteristics of the autoantibody, AIHA has been traditionally divided into warm forms, cold agglutinin disease (CAD), and rarer forms—mixed, atypical and paroxysmal cold hemoglobinuria.

Warm Autoimmune Hemolytic Anemia (wAIHA) is the most common type of autoimmune hemolytic anemia, comprising approximately 70–80% of all adult cases and 50% of the pediatric cases. More than half of these cases are called primary due to undefined etiology.

For a long time, wAIHA had been viewed as a rare autoimmune disease that could be treated empirically, on a long-term basis, mainly by corticosteroids. It is a chronic disease and even after response to steroids, individuals have a >60% probability of relapse after steroid tapering and withdrawal. Further understanding of the pathogenesis and the variability of the disease will be necessary to optimally tailor individualized treatment strategies with the goal of optimal efficacy with the lowest possible short- and long-term toxicity

Warm Autoimmune Hemolytic Anemia Epidemiology

The Warm Autoimmune Hemolytic Anemia epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Warm autoimmune hemolytic anemia epidemiology segmented as the Total Prevalent Cases of Autoimmune Hemolytic Anemia, Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia, Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia, Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia. The report includes the prevalent Warm autoimmune hemolytic anemia symptoms in 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2021 to 2034.

Country-wise Warm Autoimmune Hemolytic Anemia Epidemiology

The epidemiology segment also provides the Warm Autoimmune Hemolytic Anemia epidemiology data and findings across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

• The total prevalent population of Warm Autoimmune Hemolytic Anemia associated in the 7MM was estimated to be 89,747 in 2020 and expected to increase for the study period, i.e., 2021-2034.
• Among the EU5 countries, Germany had the highest prevalent population of Warm Autoimmune Hemolytic Anemia followed by France.

Scope of the Report

• Warm Autoimmune Hemolytic Anemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
• Warm Autoimmune Hemolytic Anemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Warm autoimmune hemolytic anemia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• The report provides insight into the historical and forecasted patient pool of Warm Autoimmune Hemolytic Anemia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• The report helps recognize the growth opportunities in the 7MM concerning the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Warm Autoimmune Hemolytic Anemia
• The report provides the segmentation of the Warm autoimmune hemolytic anemia epidemiology by Prevalent Cases of Warm Autoimmune Hemolytic Anemia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• The report provides the segmentation of the Warm Autoimmune Hemolytic Anemia epidemiology by severity-specific Prevalent Cases of Warm Autoimmune Hemolytic Anemia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan

Report Highlights

• 10-year Forecast of Warm Autoimmune Hemolytic Anemia epidemiology
• United States Coverage
• Total Prevalent Cases of Warm Autoimmune Hemolytic Anemia
• Prevalent Cases according to segmentation: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia

KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM concerning the patient population about Warm Autoimmune Hemolytic Anemia?
• What are the key findings of Warm Autoimmune Hemolytic Anemia epidemiology across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan and which type will have the highest number of patients during the forecast period (2021-2034)?
• What would be the total number of patients with Warm Autoimmune Hemolytic Anemia across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan during the forecast period (2021-2034)?
• At what CAGR the patient population is expected to grow during the forecast period (2021-2034)?
• What are the disease risk, burden, and unmet needs of Warm Autoimmune Hemolytic Anemia?
• What are the currently available treatments for Warm Autoimmune Hemolytic Anemia?

Reasons to buy

• The Warm Autoimmune Hemolytic Anemia Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Warm Autoimmune Hemolytic Anemia market
• Quantify patient populations in the global Warm Autoimmune Hemolytic Anemia market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Warm Autoimmune Hemolytic Anemia therapeutics in each of the markets covered
• Understand the magnitude of Warm Autoimmune Hemolytic Anemia population by its prevalent cases
• Understand the magnitude of Warm Autoimmune Hemolytic Anemia population by its type-specific cases
• The Warm Autoimmune Hemolytic Anemia epidemiology report and model was written and developed by Masters and PhD level epidemiologists
• The Warm Autoimmune Hemolytic Anemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population